Case Report

Occult insulinoma after oesophagectomy for oesophageal cancer—diagnostic challenges

Marta Alexandre Silva1*, Maria João Amaral1,2, Pedro Pinto1, Mónica Martins1, Marco Serôdio1,2, Dírcea Rodrigues3, Vânia Almeida4, José Guilherme Tralhão1,2,5

INTRODUCTION

Hypoglycaemia in the post-operative period is mainly iatrogenic (related to anti-hyperglycaemic drugs), but can also be explained by an endogenous hyperinsulimemic state. In the context of previous gastrointestinal surgery, a form of dumping syndrome can mask hypoglycaemia from an underlying cause, such as an insulinoma. The authors present a clinical case of a male patient who underwent oesophageal surgery for an oesophago-gastric junction adenocarcinoma and developed hypoglycaemic symptoms in the post-operative period, caused by an undiagnosed insulinoma. This case report portrays the diagnostic investigation of a hypoglycaemia state in the post-operative period, narrowing to the workup of an endogenous hyperinsulimemic hypoglycaemia and provides a summary of insulinoma’s treatment. An insulinoma should always be considered in a patient with endogenous hyperinsulimemic hypoglycaemia, even with a history of oesophago-gastric surgery.

Keywords: Oesophageal cancer, Dumping syndrome, Endogenous hyperinsulimemic Hypoglycaemia, Insulinoma

ABSTRACT

Hypoglycaemia in the post-operative period is mainly iatrogenic (related to anti-hyperglycaemic drugs), but can be explained by an endogenous hyperinsulimemic state. In the context of previous gastrointestinal surgery, a form of dumping syndrome can mask hypoglycaemia from an underlying cause, such as an insulinoma. The authors present a clinical case of a male patient who underwent oesophageal surgery for an oesophago-gastric junction adenocarcinoma and developed hypoglycaemic symptoms in the post-operative period, caused by an undiagnosed insulinoma. This case report portrays the diagnostic investigation of a hypoglycaemia state in the post-operative period, narrowing to the workup of an endogenous hyperinsulimemic hypoglycaemia and provides a summary of insulinoma’s treatment. An insulinoma should always be considered in a patient with endogenous hyperinsulimemic hypoglycaemia, even with a history of oesophago-gastric surgery.

Keywords: Oesophageal cancer, Dumping syndrome, Endogenous hyperinsulimemic Hypoglycaemia, Insulinoma

INTRODUCTION

Hypoglycaemia in the post-operative period is mainly iatrogenic (related to antihyperglycaemic drugs), but can also be a consequence of reduced nutritional intake, sepsis, hormone deficiency (such as hypothyroidism or hypocortisolism), non-islet cell tumour or endogenous hyperinsulimism.1

Dumping syndrome (DP) is a common complication of oesophago-gastric surgery. Symptoms of late dumping syndrome usually occur between 1 to 3 h after a meal and are primarily the manifestations of hypoglycaemia.2 In the context of previous gastrointestinal surgery, a form of dumping syndrome can mask hypoglycaemia from an underlying cause, such as an insulinoma.1

Insulinoma is the most frequent functioning form of pancreatic neuroendocrine neoplasm (NEN). Its incidence is estimated at 4 per million people a year.4 Although rare, it’s the most common cause of hyperinsulimemic hypoglycaemia, usually occurring in the fasting state but occasionally in the postprandial period.1 The diagnosis of insulinoma is based on biochemical tests (with measurement of plasma glucose, insulin, C-peptide and proinsulin) and imaging tests (such as CT, MRI and PET scan).5 Recently, PET scan with 68Ga-DOTA conjugated peptides (such as 68Ga-DOTA-NOC) brought an improvement in diagnosis of insulinoma, for its high

1Department of General Surgery, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
2Faculty of Medicine, University of Coimbra
3Department of Endocrinology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
4Department of Pathology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
5Coimbra Institute for Clinical and Biomedical Research (ICBR) area of Environment, Genetics and Oncobiology (CIMAGO), Faculty of Medicine, University of Coimbra

Received: 17 November 2021
Accepted: 07 December 2021

*Correspondence:
Dr. Marta Alexandre Silva,
E-mail: mafr.silva@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

DOI: https://dx.doi.org/10.18203/2349-2902.isj20215154
affinity for type 2, 3 and 5 somatostatin receptors which are present in pancreatic neuroendocrine tumours; however, \(^{68}\text{Ga-DOTA-exendin-4}\) PET-CT-targeting glucagon-like peptide 1 receptor (GLP-1R) is considered the most sensitive diagnostic tool but it’s not available in all centers.\(^{6,7}\)

The authors present a clinical case of a male patient who underwent oesophageal surgery for an oesophago-gastric junction adenocarcinoma and developed hypoglycaemic symptoms only in the post-operative period, caused by an undiagnosed insulinoma.

This case demonstrates an uncommon presentation of an insulinoma (following oesophageal surgery) and its diagnostic challenge, due to the similarities with dumping syndrome. Indeed, insulinoma remains an important diagnosis to exclude in both post-prandial or fasting hyperinsulinaemic hypoglycaemia.\(^3\)

**CASE REPORT**

A 65-year-old male patient was referred to our oesophageal cancer reference center, with a diagnosis of oesophago-gastric junction (EGJ) adenocarcinoma (Siewert I). His past medical history included vocal cord malignancy (submitted to laryngectomy and cervical radiotherapy in 1994) related to previous tobacco abuse. The patient was asymptomatic and the diagnosis was made with a biopsy during a screening upper endoscopy. No metastasis or other pathologic findings were found on pre-operative studies (thoraco-abdominopelvic computed tomography-TAP-CT and \(^{18}\text{F-fluorodeoxyglucose positron-emission tomography CT-^{18}\text{F-FDG PET-CT}}\)).

Our patient underwent a minimal invasive radical subtotal oesophagectomy (Ivor-Lewis). In post-op period, he developed thoracic empyema that was percutaneously drained and was discharged on postoperative day 10, without further complications. Histology revealed oesophageal adenocarcinoma (pT2N0M0).

One month after hospital discharge, the patient presented to the emergency room with fasting severe symptomatic hypoglycaemia (35 mg/dL), which was corrected with intravenous dextrose (Whipple’s triad), and dysphagia. The patient had no history of abdominal pain or diarrhea. He was admitted to the general surgery ward with the presumptive diagnosis of food intake impairment/late DP. Despite endoscopic confirmation of anastomotic patency and a strict nutritional control, the patient maintained asymptomatic fasting hypoglycaemic episodes and was transferred to the endocrinology ward.

**Investigations**

After hypoglycaemic drugs were excluded and in the absence of a sepsis or other critical illness, a workup was made during a spontaneous hypoglycaemia with measurement of plasma glucose, insulin, anti-insulin antibodies, C-peptide, TSH, T4, cortisol, ACTH, growth hormone and insulin grow-factor (IGF) concentrations. Plasma insulin and C-peptide levels were elevated (17 \(\mu\text{U/mL}\) and 4, 6 ng/mL, respectively) and plasma glucose was low (50 mg/dL), consistent with endogenous hyperinsulinemic hypoglycaemia (EEH). An autoimmune hypoglycaemic state was excluded since insulin antibodies were negative. Thyroid hormone function and ACTH/cortisol/growth hormone and IGF plasma concentrations were normal.

The patient was treated with diazoxide and an abdominal CT scan with intravenous contrast was repeated, looking for an insulinoma, a 21x19 mm nodular lesion was now apparent on the pancreatic neck (Figure 1). \(^{68}\text{Ga-DOTA-NOC PET CT}\) confirmed the diagnosis of insulinoma (Figure 2).
Treatment and outcome

Given the imagiological confirmation of insulinoma, the patient underwent a laparotomic distal pancreatectomy with splenic preservation. In the postoperative period a grade B pancreatic fistula was found, leading to an intrabdominal collection that was percutaneously drained.

On gross examination of the surgical specimen there was a 15x10x14 mm nodular lesion of the pancreas, formed by pale tissue with soft consistency and haemorrhagic areas. Histological examination showed a grade 1 neuroendocrine pancreatic tumour (neoplastic cells expressed Ck cam 5.2, chromogranin, synaptophysin, insulin and amyloid; Ki 67 <3%) (Figure 3).

At three months follow-up the patient was asymptomatic, with normal glucose levels, without diazoxide or any additional medication and maintained adequate oral nutritional intake.

DISCUSSION

We report a case of an occult insulinoma, symptomatic only about one month after an Ivor-Lewis oesophagectomy for oesophageal cancer. By the time of diagnosis and staging of the oesophageal adenocarcinoma, the patient was asymptomatic and the pancreatic lesion was not found on the first CT or ¹⁸F-FDG PET-CT scans.

Given the recent oesophageal surgery and the concomitant complaint of dysphagia, two main differential diagnoses were considered for the hypoglycaemic state of our patient-food intake impairment due to anastomotic stenosis and late DP.

Benign anastomotic stenosis are relatively frequent after oesophagectomy (10 to 56% in some series), mainly with cervical anastomosis; the prophylactic use of protonpump inhibitors and endoscopic dilatation techniques have reduced the morbidity related to this complication.⁷,⁹ In this case, this hypothesis was disregarded given the anastomotic patency proved by endoscopy.

DP is a known complication following upper gastrointestinal surgery, including oesophagectomy (with a reported incidence as high as 50%), but its symptoms are severe and persistent in only 10% of cases.²,¹⁰ DP symptoms’ are experienced after ingestion of a meal, as a consequence of rapid gastric emptying of food to the small intestine.¹⁰ Early DP (within an hour, after the meal) is a consequence of a rapid passage of osmotically active particles into the small intestine, causing gastrointestinal and vasomotor symptoms; on the other hand, late DP (one to 3 hours after a meal) is attributed to reactive hypoglycaemia induced by a rise in insulin plasmatic levels.¹⁰,¹¹ The treatment of this complication relies mainly on dietary changes (smaller and more frequent meals, excluding liquids from meals, decreasing carbohydrate intake, preferring complex carbohydrates).¹⁰ In our case, the patient still maintained fasting hypoglycaemic episodes even with strict dietary control and a further investigation was pursued; also, the hypoglycaemic profile (fasting rather than post-prandial) raised awareness for other causes.

After excluding other frequent hypoglycaemic causes in the post-operative period including exogenous administration of insulin/insulin secretagogue/other hypoglycaemic drugs (such as indomethacin, pentamidine, glucagon), sepsis and hormone deficiency, workup was directed towards finding of an EHH.

The diagnosis of EHH is biochemical and requires blood glucose <55 mg/dL, insulin ≥3 µU/mL, C-peptide ≥0.6 ng/mL and proinsulin levels ≥5 pmol/L. When hypoglycaemic syndrome is severe these criteria can be evaluated on a fasting blood test; when the clinical or biochemical conditions are not clear, 72 hour fasting test remains the gold standard for diagnosis. C-peptide levels are important in order to exclude administration of exogenous insulin as the cause of hypoglycaemia. Insulinomas are the most frequent cause of EHH; however, other causes must be considered: hypoglycaemia consequent to upper gastrointestinal surgery due to neisidioblastosis of pancreatic tissue-non insulinoma pancreaticanogenous hypoglycaemia syndrome (NIPHS) and insulin autoimmune hypoglycaemia.¹,²,³ As referred before, in our case insulin autoimmune hypoglycaemia was excluded and localisation/imagiological studies found a nodular
pancreatic lesion, pointing for an insulinoma rather than NIPHS as cause for this hypoglycaemic state.

Insulinomas are functioning NEN and more than 99% are located in the pancreas. They originate from the neuroendocrine islet cells or multipotent stem cells of the pancreas and produce insulin independently of glucose level’s stimuli; as pointed before, they are the most common cause of EEH syndrome.12 The main clinical manifestations of insulinomas are hypoglycaemia-related symptoms. They should be suspected in patients with autonomic and/or neuroglycopenic symptoms or signs, blood glucose <55 mg/dL and resolution of those symptoms or signs after the plasma glucose concentration is raised.1 This Whipple’s triad defines the pathognomonic presentation of this disease.12,13

One of the curious findings in our case is the appearance of the insulinoma-related symptoms only after oesophagectomy. This could be explained by two theories: first, the expected decreased oral intake after this type of surgery lowered the patient’s normal glucose plasmatic concentration that were not compensated with a reduced insulin production, leading to a symptomatic hypoglycaemia; second, the change in the gastrointestinal architecture contributing to a rapid gastric emptying could induced a further rise in insulin secretion by the normal pancreatic β-cells (due to a higher incretin secretion), besides the autonomous insulin production by the insulinoma.

The other interesting fact was that the first CT study was unable to detect the insulinoma. This could be explained because typical imaging protocol used to stage hypovascular tumors-such as an adenocarcinoma-only includes a portal venous phase acquisition after intravenous contrast administration whereas a hyper-vascular lesion-such as an insulinoma-is better depicted in an early arterial (pancreatic) phase.

In our literature review, we found only one case of an occult insulinoma and a coexisting oesophageal carcinoma14, which shows the rarity of this clinical scenario. In that report, the carcinoma of the esophagus (with lymph node and hepatic metastasis) didn’t show increased radioactivity on 68Ga-DOTA-exendin-4 PET-CT (contrary to the insulinoma), being found by 18F-FDG PET-CT. 68Ga-DOTA-exendin-4 PET-CT is a PET tracer targeting GLP-1R, which is highly overexpressed on benign insulinoma cell surface. Most insulinomas are benign and usually very small (<2 cm), making it difficult to localize with the current imaging techniques, such as CT scans.7 According to a metanalysis, 68Ga-DOTATATE PET-CT is clinically equivalent or superior to octreotide imaging and should be used when available (which is not the case in our country).15

Medical treatment for insulinomas can be used for preventing hypoglycaemia in insulinomas with unknown location or previously to surgical intervention. Possible choices, besides intravenous glucose infusion, are diazoxide, somatostatin analogues (SSA), everolimus and glucocorticoids.12,13 Diazoxide is used as a first-line treatment for glycaemic control in patients with insulinomas preoperatively but also in cases of persistent hypoglycaemia after surgery.12 It also can be used safely and effectively, on a long term basis, when it cannot be localized or removed surgically and SSA represent a good alternative, specially used in patients who cannot undergo surgical intervention and when diazoxide is not recommended due to adverse effects or inefficacy.12,16-18 In cases of malignant insulinoma, SSA can also be considered first-line treatment because of their anti-proliferative effect. Everolimus can be used for refractory hypoglycaemia and glucocorticoids are only used when better pharmacological options were not available.12

Surgery is still the ideal treatment for patients with insulinoma, controlling symptoms of hypoglycaemia, with an overall cure rate up to 98%.7 Given that insulinomas are usually solitary, well-capsulated, small and benign in more than 90% of cases, enucleation of the tumour is the ideal surgical approach, minimizing the risk of exocrine and endocrine insufficiency associated with an anatomic resection.10 However, the proximity of the pancreatic lesion to the Wirsung duct made an enucleation not feasible in our case and we performed a distal pancreatectomy with splenic preservation.

Besides the diagnostic challenge in this case, there were also technical concerns during the surgical procedure, as we needed to preserve the gastric blood flow to the gastric tube (assured by the right gastroepiploic artery, a branch of the gastroduodenal artery). In fact, the integrity of the gastroduodenal artery could be jeopardized during pancreatic dissection and was a main concern in this case. This challenge (in addition to adhesions from previous oesophageal surgery) made a laparoscopic approach not feasible.

CONCLUSION

In summary, this case report illustrates an uncommon presentation of an insulinoma and the diagnostic challenges due to the time of presentation (after oesophago-gastric surgery), reminding us to always consider this entity in a patient with endogenous hyperinsulinemic hypoglycaemia.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: Not required

REFERENCES

1. Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, Seaquist ER et al. Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2009;94(3):709-28.
2. Scarpellini E, Arts J, Karamanolis G, Laurenius A, Siquini W, Suzuki H et al. International consensus on the diagnosis and management of dumping syndrome. Nat Rev Endocrinol. 2020;16(8):448-66.

3. Qian SY, Hare MJL, Pham A, Topliss DJ. Insulinoma presenting with post-prandial hypoglycaemia following fundoplication. Endocrinol Diabetes Metab Case Rep. 2018;2018.

4. Caldas AR, Teixeira S, Giestas A, Amaral C, Cardoso MH. Insulinoma pancreático: casuística de um hospital central e revisão da literatura. Rev Port Endocrinol Diabetes e Metab. 2016;11(2):181-7.

5. Rostambeigi N, Thompson GB. What should be done in an operating room when an insulinoma cannot be found? Clin Endocrinol (Oxf). 2009;70(4):512-5.

6. Tuzcu SA, Pekkolay Z, Kılınç F, Tuzcu AK. 68 Ga-DOTATATE PET/CT Can Be an Alternative Imaging Method in Insulinoma Patients. J Nucl Med Technol. 2017;45(3):198-200.

7. Göemes M, Rahman SA, Kapoor RR, Flanagan S, Houghton JAL, Misra S et al. Hyperinsulinemic hypoglycemia in children and adolescents: Recent advances in understanding of pathophysiology and management. Rev Endocr Metab Disord. 2020;21(4):577-97.

8. Orringer MB, Marshall B, Iannettoni MD. Eliminating the cervical esophagogastric anastomotic leak with a side-to-side stapled anastomosis. J Thorac Cardiovasc Surg. 2000;119(2):277-88.

9. Lerut T, Coosemans W, Decker G, De Leyn P, Nafteu P, van Raemdonck D. Anastomotic Complications after Esophagectomy. Dig Surg. 2002;19(2):92-8.

10. Berg P, McCallum R. Dumping Syndrome: A Review of the Current Concepts of Pathophysiology, Diagnosis, and Treatment. Dig Dis Sci. 2016;61(1):11-8.

11. Anandavadivelan P, Wikman A, Malberg K, Martin L, Rosenlund H, Rueb C et al. Prevalence and intensity of dumping symptoms and their association with health-related quality of life following surgery for oesophageal cancer. Clin Nutr. 2021;40(3):1233-40.

12. Spada F, Rossi RE, Kara E, Laffi A, Massironi S, Rubino M et al. Carcinoid Syndrome and Hyperinsulinemic Hypoglycemia Associated with Neuroendocrine Neoplasms: A Critical Review on Clinical and Pharmacological Management. Pharmaceuticals. 2021;14(6):539.

13. Amaral MJ, Alexandrino H, Meireles D, Oliveira RC, Serodio M, Tralhao JG. You are not yourself when you are hungry: a rare case of malignant insulinoma. Int Surg J. 2020 Jan 25;7(7):2378.

14. Luo Y, Li N, Kiesewetter DO, Chen X, Li F. 68Ga-NOTA-Exendin-4 PET/CT in Localization of an Occult Insulinoma and Appearance of Coexisting Esophageal Carcinoma. Clin Nucl Med. 2016;41(4):341-3.

15. Deppen SA, Blume J, Bobbey AJ, Shah C, Graham MM, Lee P, et al. 68 Ga-DOTATATE Compared with 111 In-DTPA-Octreotide and Conventional Imaging for Pulmonary and Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis. J Nucl Med. 2016;57(6):872-8.

16. Warren AM, Topliss DJ, Hamblin PS. Successful medical management of insulinoma with diazoxide for 27 years. Endocrinol Diabetes Metab Case Reports. 2020 Oct 6;2020.

17. Yasuda A, Seki T, Kitajima N, Baba T, Sasaki N, Kametani Y et al. A case of insulinoma effectively treated with low-dose diazoxide. Clin Case Reports. 2020;8(10):1884-9.

18. Gilliaux Q, Bertrand C, Hanon F, Donckier JE. Preoperative treatment of benign insulinoma: diazoxide or somatostatin analogues? Acta Chir Belg. 2020 May 18:1-4.

19. Manjunath P, George B, Mathew V, Bantwal G, Ayyar V. Riding high on low fuel-Our experience with endogenous hyperinsulinemic hypoglycemia. Indian J Endocrinol Metab. 2017;21(5):655.